Literature DB >> 7740422

Clinical pilot study on high-dose intraarterial chemotherapy with direct hemoperfusion under hepatic venous isolation in patients with advanced hepatocellular carcinoma.

Y Ku1, T Fukumoto, T Iwasaki, M Tominaga, M Samizo, T Nishida, Y Kuroda, S Hirota, M Sako, H Obara.   

Abstract

BACKGROUND: We recently developed a novel system of direct hemoperfusion under hepatic venous isolation in an attempt to achieve high-dose intraarterial chemotherapy for patients with malignant liver tumors. We report here the results of treatment of these patients with advanced hepatocellular carcinoma.
METHODS: Adriamycin (100 to 150 mg/m2) was administered into the hepatic artery of 15 patients, under conditions of extracorporeal drug elimination by direct hemoperfusion under hepatic venous isolation. Hepatic venous isolation was accomplished mainly by the double-balloon technique with an occlusion catheter and a balloon catheter. The isolated hepatic venous blood was filtered by direct hemoperfusion and pumped to the left axillary vein.
RESULTS: During 5 minutes of adriamycin infusion, the mean drug extraction ratios of the direct hemoperfusion filters were 91% +/- 9% (mean +/- SD). The amount of drug removed by the system was 26.4% +/- 16.0% of the amount of drug administered. Two patients died, one of necrotizing pancreatitis and the other of hepatic arterial thrombosis. Both deaths were related directly to the hepatic arterial catheter. Other side effects included hemolysis related to the system of hemoperfusion (87%), chemical hepatitis (80%), leukopenia less than 3000/mm3 (67%), alopecia (33%), and nausea and vomiting (20%). Nine (64%) of 14 evaluable patients had objective tumor responses, with a median duration of response of 6.2 months.
CONCLUSIONS: This approach offers an effective therapeutic option for patients with advanced hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7740422     DOI: 10.1016/s0039-6060(05)80250-8

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

1.  Percutaneous hepatic venous isolation and extracorporeal charcoal hemoperfusion for high-dose intraarterial chemotherapy in patients with colorectal hepatic metastases.

Authors:  Y Ku; M Tominaga; T Iwasaki; T Kitagawa; I Maeda; M Shiotani; S Kusunoki; Y Maekawa; M Samizo; T Fukumoto; Y Kuroda; S Hirota; Y Saitoh
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

2.  Induction of long-term remission in advanced hepatocellular carcinoma with percutaneous isolated liver chemoperfusion.

Authors:  Y Ku; T Iwasaki; T Fukumoto; M Tominaga; S Muramatsu; N Kusunoki; T Sugimoto; Y Suzuki; Y Kuroda; Y Saitoh; M Sako; S Matsumoto; S Hirota; H Obara
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

3.  New macroscopic classification and back-flow thrombectomy for advanced hepatocellular carcinoma with portal vein tumor thrombus invading the contralateral second portal branch.

Authors:  Takumi Fukumoto; Masahiro Kido; Atsushi Takebe; Motofumi Tanaka; Hisoka Kinoshita; Kaori Kuramitsu; Shohei Komatsu; Daisuke Tsugawa; Tadahiro Goto; Sadaki Asari; Hirochika Toyama; Tetsuo Ajiki; Yonson Ku
Journal:  Surg Today       Date:  2017-03-21       Impact factor: 2.549

4.  Development and Validation of Endovascular Chemotherapy Filter Device for Removing High-Dose Doxorubicin: Preclinical Study.

Authors:  Anand S Patel; Maythem Saeed; Erin J Yee; Jeffrey Yang; Gregory J Lam; Aaron D Losey; Prasheel V Lillaney; Bradford Thorne; Albert K Chin; Sheena Malik; Mark W Wilson; Xi C Chen; Nitash P Balsara; Steven W Hetts
Journal:  J Med Device       Date:  2014-08-19       Impact factor: 0.582

5.  Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma.

Authors:  Yonson Ku; Takeshi Iwasaki; Masahiro Tominaga; Takumi Fukumoto; Tetsuya Takahashi; Masahiro Kido; Satoshi Ogata; Masanori Takahashi; Yoshikazu Kuroda; Shinichi Matsumoto; Hidefumi Obara
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

Review 6.  Percutaneous Isolated Hepatic Perfusion for the Treatment of Unresectable Liver Malignancies.

Authors:  Mark C Burgmans; Eleonora M de Leede; Christian H Martini; Ellen Kapiteijn; Alexander L Vahrmeijer; Arian R van Erkel
Journal:  Cardiovasc Intervent Radiol       Date:  2015-12-30       Impact factor: 2.740

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.